Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 18,752 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions: Carboplatin, Paclitaxel, Sapanisertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Lymphoma
Interventions: Pazopanib, Pazopanib (GW786034)(GW786034); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Interventions: Allogeneic Mesenchymal Bone Marrow Cells; Biological
Lead sponsor: Stemedica Cell Technologies, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 2
States / cities: La Mesa, California • San Diego, California

Conditions: Malignant Pleural Effusion, Malignant Ascites
Interventions: Tocilizumab; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Danicopan: Powder-In-Capsule 1, Danicopan: Powder-In-Capsule 2, Danicopan: Tablet; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Honokiol; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist; Drug · Radiation · Genetic
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Isocitrate Dehydrogenase Gene Mutation
Interventions: HMPL-306; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Orange, California • Atlanta, Georgia • Worcester, Massachusetts + 4 more

Conditions: Healthy Participants
Interventions: BMS-986235 (Treatment A), Rifampin (Treatment B); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lung Cancer
Interventions: porfimer sodium, bronchoscopy; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: GMI-1271, Placebo, Enoxaparin Sodium (Lovenox®); Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
Interventions: CX-2029; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more

Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
Interventions: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Infection
Interventions: Zidovudine (AZT) & Interleukin-2 (IL2); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: 2S, 4R Ketoconazole (DIO-902); Drug
Lead sponsor: DiObex; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Omaha, Nebraska • Portland, Oregon + 2 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Iodine-131 Anti-B1 Antibody; Drug
Lead sponsor: Corixa Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Palo Alto, California • New Hyde Park, New York

Conditions: Alzheimer Disease
Interventions: AC-OLE-01-VA; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions: Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Ischemic Stroke
Interventions: SB623; Biological
Lead sponsor: SanBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 5
States / cities: Birmingham, Alabama • Stanford, California • Atlanta, Georgia + 2 more

Conditions: Maternal Substance Use, Child Abuse and Neglect
Interventions: Mentalizing Therapy for Substance Using Mothers, Standard Parent Education for Substance Using Mothers; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Carcinoma, Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer
Interventions: External Beam Accelerated Partial Breast Irradiation; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-small Cell Lung Cancer Stage I
Interventions: Ad5-yCD/mutTKSR39rep-ADP Adenovirus; Biological
Lead sponsor: Benjamin Movsas, M.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: questionnaire administration, survey administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Nashville, Tennessee

Search by objective public record fields.

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Study of the Metabolism of Danicopan in Healthy Adults

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

A Study of Modified Stem Cells in Stable Ischemic Stroke

Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

Self-Care for Lymphedema in Patients With Breast Cancer